TARS - Tarsus Pharmaceuticals, Inc.
About Tarsus Pharmaceuticals, Inc. (https://www.tarsusrx.com)
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Bobak R. Azamian | Co-Founder, President, Chief Executive Officer & Chairman | – | $1,318,208 USD |
| Jeffrey S. Farrow | Chief Financial Officer & Chief Strategy Officer | 1962 | $888,645 USD |
| Seshadri Neervannan | Chief Operating Officer | 1968 | $839,200 USD |
| Aziz Mottiwala | Chief Commercial Officer | 1978 | $821,650 USD |
| Bryan Wahl | General Counsel & Corporate Secretary | 1978 | $771,233 USD |
| Dianne C. Whitfield | Chief Human Resources Officer | 1977 | $578,900 USD |
| Elizabeth Yeu | Chief Medical Officer | 1978 | $156,691 USD |
| Adrienne Kemp | Senior Director of Corporate Communications | – | – |
| Cara Miller | Senior Vice President of Corporate Affairs | – | – |
| David Nakasone | Head of Investor Relations | – | – |
| Matthew Rossen | Vice President of Marketing | 1978 | – |
| Neera Clase | Senior Vice President of Market Access | – | – |
| Scott Youmans | Vice President of Sales | – | – |